Pay-for-Responder scheme for NHS and private patients
Since June 2012, Bayer has provided financial support to help prescribers identify those patients with multiple sclerosis (MS) being treated on the NHS who will derive most benefit from treatment with Sativex.*
Under the terms of the programme, Bayer funds the first pack of Sativex (3 x 10ml vials) for all new patients within the licensed indication.
Following requests from customers, this Pay-for-Responder scheme is now being extended to private patients.
This website has been developed to provide you with easy access to electronic order forms for your convenience, should you wish to participate in the scheme. Please ensure that you have referred to the terms and conditions of the offer.
*Sativex is indicated for symptom improvement in adult patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy (1).
- Sativex Summary of Product Characteristics.